Recently, Mr. Kong Fanxing, Executive Director，Chairman, and CEO of Fehorizon, met with Professor Koji Tanabe (founder of the Japanese company I Peace) and Professor Liu Xiaodong (chief scientist of the Chinese company iCamuno Biotherapeutics) at the FEHORIZON Plaza in Shanghai. They had in-depth exchanges regarding internationally advanced cell medicine researches and applications at present, and discussed the upgrade and development of the healthcare industry. Mr. Li Jiancheng (Vice President of Fehorizon and General Manager of Horizon Healthcare) and Mr. Xu Huibin (Assistant President of Fehorizon) were also present at the meeting.

▲General Manager Li Jiancheng (first from right) showed the Japanese guests around the Company’s gallery and introduced Horizon Healthcare

CEO Kong Fanxing welcomed Professor Koji Tanabe and Professor Liu Xiaodong. He indicated that Horizon Healthcare is a significant component of Fehorizon’s strategic layout under its “finance + industry” development mode; the Company not only provides healthcare-related enterprises with one-stop integrated financial services, but also offers medical services through nearly 30 member hospitals under Horizon Healthcare, with focus on improving healthcare services for the people of third-tier, fourth-tier and fifth-tier cities and counties lacking medical resources. 

CEO Kong pointed out that cell medicine is an important development direction of medicine in the future, and has great potential to improve the human health condition and the life quality of the elderly population. The two scientists have achieved world-renowned research findings in their respective fields, and hope to cooperate on medical research, R&D and application of products, etc. while exploring the new mode of “serving enterprises and serving entrepreneurs.”

▲CEO Kong Fanxing at the meeting

Professor Koji Tanabe appreciated Fehorizon’s continuous attention to cutting-edge healthcare technologies of the world, and introduced relevant research findings. With “guarding a healthy and happy life with cell technology” as the goal, I Peace helps individuals with health management and disease treatment, meanwhile constructing a comprehensive platform that links up individuals, research institutes, and healthcare-related enterprises. On account of Fehorizon’s profound resource accumulation in mainland China, Hong Kong (China) and Southeast Asia, Professor Koji Tanabe expressed hopes for joining hands with Fehorizon to urge more excellent enterprises to engage in relevant R&D and applications and together promote the advancement of medicine as well as the development of healthcare.

▲Professor Koji Tanabe (first from right) at the meeting

At the meeting, Professor Liu Xiaodong emphasized on the latest R&D progress of iCamuno Biotherapeutics. According to Professor Liu, to scientifically delay aging and reduce the influence of related diseases has become the focus of bioscience worldwide, and iCamuno Biotherapeutics is devoted to promoting the innovation of tumor immunotherapy and regenerative therapy treatments with focus on the underlying technology of iPSC. He expressed hopes for promoting the innovative development of the healthcare industry together with Fehorizon, and grasping new opportunities brought by new trends and new technologies of medicine.

▲Professor Liu Xiaodong (first from left) at the meeting

Other leaders present at the meeting are: Riko Maruyama from I Peace, COO He Zhiyong of iCamuno Biotherapeutics, and relevant personnel of Fehorizon, including Deputy General Manager Huang Long of the Overseas Business Department and those responsible for overseas healthcare development from the Operation Center and Horizon Healthcare.

In the future, Fehorizon will continue to give play to its advantages as a “Marketization, Internationalization, and Specialization” enterprise and gather world-class scientific power to benefit domestic medical service providers with international cutting-edge resources and contribute to the transformation & upgrade and the long-term development of China’s healthcare industry.